Electromed (ELMD) Earnings Date & Reports

Key Takeaways

• Electromed, Inc. (NYSE American: ELMD) is scheduled to report its fiscal 2027 first quarter results — for the period ended September 30, 2026 — on November 10, 2026, after the market close.
• Wall Street consensus points to earnings per share (EPS) of about $0.26, compared with $0.25 in the same quarter a year earlier.
• Analysts estimate revenue of roughly $18.85 million, implying year-over-year growth of about 11.6%.
• Electromed enters the quarter on a 15-quarter streak of year-over-year revenue and profit growth, with management guiding for double-digit top-line growth in fiscal 2027.
• Investors will be watching home care demand, sales representative productivity, and gross margin durability in the low-70% range or better.
• For more context, explore Major News, Today's Price Move, Price Targets, and Forecast pages for the ticker.
• You can also discover actionable ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Electromed is a medical device company best known for its SmartVest Airway Clearance System, which delivers high-frequency chest wall oscillation (HFCWO) therapy to patients with compromised pulmonary function, including those with bronchiectasis. The company operates on a fiscal year ending June 30, so this report covers the first quarter of fiscal 2027. Because Electromed generates nearly all of its revenue domestically and relies on a direct-to-patient sales model, quarterly results offer a timely read on referral volumes, reimbursement dynamics, and payer coverage. After a record fiscal 2026 — revenue of $73.8 million, up 15.3%, and diluted EPS of $1.30 — this print will signal whether that momentum carried into the new fiscal year and whether management's expansion plans are translating into sustained profitability.

Earnings Expectations

Consensus expectations for the fiscal 2027 first quarter call for EPS of approximately $0.26, a modest step up from $0.25 reported in the prior-year period. Analysts project revenue near $18.85 million, an increase of roughly 11.6% from a year earlier. For context, Electromed closed fiscal 2026 with fourth-quarter revenue of $19.4 million (up 11.6% year over year) and record quarterly EPS of $0.39. Management has guided for double-digit top-line growth and continued operating leverage in fiscal 2027, while targeting home care revenue per sales representative of $1,050,000 to $1,150,000 and planning to expand to about 67 territories. Key metrics investors will watch include gross margin (management expects mid-70% levels or better), direct home care revenue growth, and the pace of sales team expansion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening, making it a practical companion for earnings-focused research across sectors like healthcare and medical devices.

Market Reaction and Investor Sentiment

Sentiment heading into the print is broadly constructive, reflecting Electromed's consistent record of beating expectations and its streak of consecutive quarterly revenue and profit growth. However, the stock has shown meaningful post-earnings volatility in recent quarters, with moves in both directions following results. Key risk factors for this report include potential softness in the hospital channel — which declined 29% year over year in the fourth quarter of fiscal 2026 — as well as the leadership transition underway, given the CEO's planned retirement in April 2027. Investors will be weighing the durability of home care demand and sales representative productivity against rising selling, general, and administrative (SG&A) expenses tied to hiring.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should monitor several forward-looking signals. First, watch the trajectory of the direct home care business, which accounted for $66.6 million of fiscal 2026 revenue and remains the primary growth engine. Management's plan to expand from 64 direct sales representatives toward roughly 67 territories will be an important indicator of how quickly the company can scale while preserving productivity.

Second, keep an eye on margin trends. Electromed has committed to maintaining mid-70% or better gross margins, but SG&A spending rose 8.7% in fiscal 2026 as the company hired to support higher referral volumes. Any commentary on expense discipline and operating leverage will matter for profitability.

Finally, watch for updates on reimbursement and payer coverage. Electromed ended fiscal 2026 with contracts covering 87% of U.S. covered lives, and its Smart Order ePrescribe platform processed more than 45% of orders. Progress on electronic ordering ahead of anticipated standards from the Centers for Medicare & Medicaid Services (CMS), along with the CEO succession plan, are key catalysts that could shape the narrative through the remainder of fiscal 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations